Saltar al contenido
Salud cardiovascularRevisión de evidencia4 min read

Lowering blood pressure cut cardiovascular events in most age groups, less clearly at 85+

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. · Lancet (London, England) · 2021 · Artículo original ↗

Idea principal

In pooled data from 51 trials and 358,707 participants, each 5 mm Hg drop in systolic blood pressure lowered the hazard of major cardiovascular events by about 9% in people aged 55 to 84 (HR 0.91), with no clear benefit in those 85 and older (HR 0.99, 95% CI 0.87-1.12). Only 4788 participants were 85 or older, so the oldest group is the least certain.

Study design

Revisión de evidencia

Reading basis

Published abstract

Reading focus

Design & applicability

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Guidelines have often used age and blood pressure thresholds to decide who gets blood pressure medication, but evidence is thin for people 70 and older and for those whose pressure is not very high. The authors tested whether the effect of lowering blood pressure on major cardiovascular events differs by age and by starting blood pressure.

Población y método

Individual participant-level meta-analysis of randomised trials from the Blood Pressure Lowering Treatment Triallists' Collaboration comparing blood pressure drugs with placebo, other drug classes, or more versus less intensive treatment, each with at least 1000 person-years of follow-up per group; people with prior heart failure were excluded. Participants were grouped by age (<55, 55-64, 65-74, 75-84, 85 and over) and by baseline systolic and diastolic pressure in 10 mm Hg steps. A fixed-effects one-stage Cox model stratified by trial was used. The primary outcome combined fatal or non-fatal stroke, myocardial infarction or ischaemic heart disease, and heart failure causing death or hospital admission.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    The data covered 358,707 participants from 51 trials (median age 65 years, IQR 59-75; range 21 to 105). Age groups: 42,960 (12.0%) under 55, 128,437 (35.8%) aged 55-64, 128,506 (35.8%) aged 65-74, 54,016 (15.1%) aged 75-84 and 4788 (1.3%) 85 and older.
  2. 2
    The hazard ratio per 5 mm Hg systolic reduction was 0.82 (95% CI 0.76-0.88) under 55, 0.91 (0.88-0.95) at 55-64, 0.91 (0.88-0.95) at 65-74, 0.91 (0.87-0.96) at 75-84 and 0.99 (0.87-1.12) at 85 and older (adjusted p for interaction = 0.050). A 3 mm Hg diastolic reduction showed similar patterns.
  3. 3
    Absolute risk reductions were larger in older groups (adjusted p for interaction = 0.024).
  4. 4
    The authors found no evidence of meaningful differences in relative benefit across baseline blood pressure categories in any age group, down to below 120/70 mm Hg.

Límites e incertidumbre

  1. 1
    Few participants were 85 or older, and the interval for that group (0.87-1.12) is compatible with both benefit and no benefit.
  2. 2
    The age-by-effect interaction was borderline (p = 0.050), so differences between age groups should be read cautiously.
  3. 3
    Participants were from trials with at least 1000 person-years per group, and those with prior heart failure were excluded, so results may not cover everyone seen in practice.
  4. 4
    This reading is based on the abstract only.

Relevancia práctica

The pooled trials suggest blood pressure medication lowered cardiovascular events across a wide range of ages and starting pressures, and that age alone should not rule treatment out. The evidence is weakest after 85. Whether and how to treat is an individual decision to make with your clinician.

Tus datos

Home cuff readings, taken under the same conditions each time, help you and your clinician see whether your pressure is trending toward a target. Do not change medication based on cuff numbers alone; bring the log to your appointment.

Cómo interpretar la evidencia

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background

The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline.

Methods

We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55-64 years, 65-74 years, 75-84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission.

Findings

We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59-75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55-64 years, 128 506 (35·8%) 65-74 years, 54 016 (15·1%) 75-84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg reduction in systolic blood pressure for each age group were 0·82 (95% CI 0·76-0·88) in individuals younger than 55 years, 0·91 (0·88-0·95) in those aged 55-64 years, 0·91 (0·88-0·95) in those aged 65-74 years, 0·91 (0·87-0·96) in those aged 75-84 years, and 0·99 (0·87-1·12) in those aged 85 years and older (adjusted p_(interaction)=0·050). Similar patterns of proportional risk reductions were observed for a 3 mm Hg reduction in diastolic blood pressure. Absolute risk reductions for major cardiovascular events varied by age and were larger in older groups (adjusted p_(interaction)=0·024). We did not find evidence for any clinically meaningful heterogeneity of relative treatment effects across different baseline blood pressure categories in any age group.

Interpretation

Pharmacological blood pressure reduction is effective into old age, with no evidence that relative risk reductions for prevention of major cardiovascular events vary by systolic or diastolic blood pressure levels at randomisation, down to less than 120/70 mm Hg. Pharmacological blood pressure reduction should, therefore, be considered an important treatment option regardless of age, with the removal of age-related blood-pressure thresholds from international guidelines.

Funding

British Heart Foundation, National Institute of Health Research Oxford Biomedical Research Centre, Oxford Martin School.

Fuentes y atribución

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration.

Lancet (London, England) · 2021-08-27

DOI: 10.1016/s0140-6736(21)01921-8 ↗PubMed · 34461040 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Metaanálisis observacional

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Ensayo aleatorizado

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
·Estudio/revisión de validación

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
Salud cardiovascular →